Chester County News and Community Website
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) remains on track to seek U.S. clearance in the fourth quarter to begin clinical testing of CNTY-813, its experimental type 1 diabetes …
Century Advances Diabetes Cell Therapy Toward FDA Filing Read More
DOWNINGTOWN, PA — A Downingtown family is seeking $45,000 by January to pursue an investigational Type 1 diabetes treatment for 15-year-old Preston, a Downingtown East High School student whose eligibility …
Downingtown Teen Faces Race to Fund Diabetes Treatment Read More
WASHINGTON, D.C. — U.S. regulators authorized Abbott Diabetes Care’s Libre Duo 10 Day for people with diabetes aged 2 and older, introducing the first U.S. wearable capable of continuously monitoring …
FDA Clears Abbott Device to Continuously Track Ketones, Glucose Read More
FORT WASHINGTON, PA — Clinical guidance presented at Office Practicum’s Engage 2026 conference contributed to the early diagnosis of Type 1 diabetes in a child, allowing treatment to begin before …
Conference Education Leads to Earlier Type 1 Diabetes Diagnosis Read More PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) will present new data on its experimental type 1 diabetes cell therapy at two scientific conferences this fall, a step that comes as …
Century Therapeutics Advances Diabetes Program With Conference Talks Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has expanded the approved use of Tzield (teplizumab) to children ages 8 to 17 who have been recently diagnosed with Stage …
FDA Expands Tzield Use for Children With Type 1 Diabetes Read More WASHINGTON, D.C. — The U.S. Food and Drug Administration has cleared the first over-the-counter continuous glucose monitor for children, expanding access to glucose-tracking technology as rates of prediabetes and Type …
FDA Expands OTC Glucose Monitor Access to Children Read More PHILADELPHIA, PA — Century Therapeutics (Nasdaq: IPSC) reported new preclinical data supporting its experimental type 1 diabetes therapy CNTY-813, as the biotechnology company works toward a planned Investigational New Drug …
Century Therapeutics Advances Diabetes Cell Therapy Toward 2026 FDA Filing Read More
WASHINGTON, D.C. — Medicare beneficiaries could soon gain significantly cheaper access to certain weight-loss and diabetes-related medications under a new federal demonstration program that will cap some monthly GLP-1 prescription …
Medicare to Cap Some GLP-1 Drug Costs at $50 for Seniors Read More
WILMINGTON, DE — Catholic Charities of the Diocese of Wilmington has launched a free Diabetes Prevention Program aimed at adults at risk for Type 2 diabetes, with the first cohort …
Free Diabetes Program Launches Amid Rising Health Risks Read More